581 related articles for article (PubMed ID: 11967816)
41. Diagnosis of heart failure using urinary natriuretic peptides.
Ng LL; Geeranavar S; Jennings SC; Loke I; O'Brien RJ
Clin Sci (Lond); 2004 Feb; 106(2):129-33. PubMed ID: 13678415
[TBL] [Abstract][Full Text] [Related]
42. Brain natriuretic peptide and acute coronary syndrome.
Mazzone M; Forte P; Portale G; Mancini F; Ursella S; La Sala M; Testa A; Covino M; Pignataro G; Gentiloni Silveri N
Minerva Med; 2005 Feb; 96(1):11-8. PubMed ID: 15827538
[TBL] [Abstract][Full Text] [Related]
43. Cardiovasoactive peptides in hemodialysis patients: diagnostic tools and predictors of outcome: a review of present knowledge and future directions.
Odar-Cederlöf I; Kjellstrand CM
Hemodial Int; 2003 Jun; 7(3):222-31. PubMed ID: 19379369
[TBL] [Abstract][Full Text] [Related]
44. Vasoactive peptides during long-term follow-up of patients after cardiac transplantation.
Kirchhoff WCh; Gradaus R; Stypmann J; Deng MC; Tian TD; Scheld HH; Breithardt G; Brisse B
J Heart Lung Transplant; 2004 Mar; 23(3):284-8. PubMed ID: 15019637
[TBL] [Abstract][Full Text] [Related]
45. Atrial and brain natriuretic peptides as markers of cardiac load and volume retention in primary aldosteronism.
Kato J; Etoh T; Kitamura K; Eto T
Am J Hypertens; 2005 Mar; 18(3):354-7. PubMed ID: 15797653
[TBL] [Abstract][Full Text] [Related]
46. B-type natriuretic peptide infusions in acute myocardial infarction.
Hillock RJ; Frampton CM; Yandle TG; Troughton RW; Lainchbury JG; Richards AM
Heart; 2008 May; 94(5):617-22. PubMed ID: 17639095
[TBL] [Abstract][Full Text] [Related]
47. Interaction on metabolic clearance between A-type and B-type natriuretic peptides in patients with heart failure.
Yoshimura M; Mizuno Y; Harada E; Nakayama M; Shimasaki Y; Ito T; Nakamura S; Soejima H; Miyamoto S; Takazoe K; Ogawa H; Kugiyama K; Saito Y; Nakao K; Yasue H
Metabolism; 2000 Sep; 49(9):1228-33. PubMed ID: 11016910
[TBL] [Abstract][Full Text] [Related]
48. Prognostic value of increased plasma levels of brain natriuretic peptide in patients with septic shock.
Ueda S; Nishio K; Akai Y; Fukushima H; Ueyama T; Kawai Y; Masui K; Yoshioka A; Okuchi K
Shock; 2006 Aug; 26(2):134-9. PubMed ID: 16878020
[TBL] [Abstract][Full Text] [Related]
49. Atrial natriuretic peptide mimetics and vasopeptidase inhibitors.
Sagnella GA
Cardiovasc Res; 2001 Aug; 51(3):416-28. PubMed ID: 11476732
[TBL] [Abstract][Full Text] [Related]
50. Natriuretic peptide response to dynamic exercise in patients with atrial fibrillation.
Engelmann MD; Niemann L; Kanstrup IL; Skagen K; Godtfredsen J
Int J Cardiol; 2005 Oct; 105(1):31-9. PubMed ID: 16207542
[TBL] [Abstract][Full Text] [Related]
51. The impact of cardiac natriuretic peptide determination on the diagnosis and management of heart failure.
Mair J; Hammerer-Lercher A; Puschendorf B
Clin Chem Lab Med; 2001 Jul; 39(7):571-88. PubMed ID: 11522102
[TBL] [Abstract][Full Text] [Related]
52. Current biochemistry, molecular biology, and clinical relevance of natriuretic peptides.
Nishikimi T; Kuwahara K; Nakao K
J Cardiol; 2011 Mar; 57(2):131-40. PubMed ID: 21296556
[TBL] [Abstract][Full Text] [Related]
53. Vigorous response in plasma N-terminal pro-brain natriuretic peptide (NT-BNP) to acute myocardial infarction.
Gill D; Seidler T; Troughton RW; Yandle TG; Frampton CM; Richards M; Lainchbury JG; Nicholls G
Clin Sci (Lond); 2004 Feb; 106(2):135-9. PubMed ID: 12974669
[TBL] [Abstract][Full Text] [Related]
54. Comparison of B-type natriuretic peptides for assessment of cardiac function and prognosis in stable ischemic heart disease.
Richards M; Nicholls MG; Espiner EA; Lainchbury JG; Troughton RW; Elliott J; Frampton CM; Crozier IG; Yandle TG; Doughty R; MacMahon S; Sharpe N; ;
J Am Coll Cardiol; 2006 Jan; 47(1):52-60. PubMed ID: 16386664
[TBL] [Abstract][Full Text] [Related]
55. Prognostic value of natriuretic peptides in Chagas' disease: a 3-year follow-up investigation.
Moreira Mda C; Heringer-Walther S; Wessel N; Moreira Ventura T; Wang Y; Schultheiss HP; Walther T
Cardiology; 2008; 110(4):217-25. PubMed ID: 18073475
[TBL] [Abstract][Full Text] [Related]
56. Association of plasma atrial natriuretic peptide, N-terminal proatrial natriuretic peptide, and brain natriuretic peptide levels with coronary artery stenosis in patients with normal left ventricular systolic function.
Nishikimi T; Mori Y; Ishimura K; Tadokoro K; Yagi H; Yabe A; Horinaka S; Matsuoka H
Am J Med; 2004 Apr; 116(8):517-23. PubMed ID: 15063812
[TBL] [Abstract][Full Text] [Related]
57. Vasopeptidase inhibitors.
Sagnella GA
J Renin Angiotensin Aldosterone Syst; 2002 Jun; 3(2):90-5. PubMed ID: 12228848
[TBL] [Abstract][Full Text] [Related]
58. Brain and other natriuretic peptides: molecular aspects.
Vanderheyden M; Bartunek J; Goethals M
Eur J Heart Fail; 2004 Mar; 6(3):261-8. PubMed ID: 14987574
[TBL] [Abstract][Full Text] [Related]
59. Plasma levels of natriuretic peptide type B and A in children with heart disease with different types of cardiac load or systolic dysfunction.
Westerlind A; Wåhlander H; Berggren H; Lundberg PA; Holmgren D
Clin Physiol Funct Imaging; 2008 Jul; 28(4):277-84. PubMed ID: 18476995
[TBL] [Abstract][Full Text] [Related]
60. Pathophysiologic relevance of measuring the plasma levels of cardiac natriuretic peptide hormones in humans.
Clerico A; Iervasi G; Mariani G
Horm Metab Res; 1999 Sep; 31(9):487-98. PubMed ID: 10569249
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
